Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 12/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 4/20 | 0.36 |
| ▸ | INSR | P06213 | 3/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | LYN | P07948 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | MARK3 | P27448 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14312351 | 1.00 | ACVRL1 (0.40) | ACVRL1TNK2IGF1RINSRPLK4 | |
| SCHEMBL14313135 | 0.93 | ACVRL1 (0.49) | ACVRL1TNK2IGF1RMERTK | |
| SCHEMBL16508292 | 0.93 | ACVRL1 (0.49) | ACVRL1TNK2IGF1RMERTK | |
| SCHEMBL16508303 | 0.89 | ACVRL1 (0.44) | ACVRL1TNK2IGF1RINSR | |
| SCHEMBL14312999 | 0.89 | ACVRL1 (0.44) | ACVRL1TNK2IGF1RINSR | |
| SCHEMBL14312666 | 0.85 | ACVRL1 (0.45) | ACVRL1TNK2IGF1RINSRMERTK | |
| SCHEMBL14312731 | 0.84 | ACVRL1 (0.46) | ACVRL1TNK2IGF1RINSRMERTK | |
| SCHEMBL5077195 | 0.84 | CA2 (0.36) | ACVRL1TNK2IGF1RINSR | |
| SCHEMBL16508304 | 0.84 | CA2 (0.36) | ACVRL1TNK2IGF1RINSR | |
| SCHEMBL5074844 | 0.83 | ACVRL1 (0.43) | ACVRL1TNK2IGF1RINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | IGF1R, FGFR1, IGFBP1 | ACVRL1 336/4885TNK2 356/4885IGF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.